PROGNOSTIC FACTORS ASSOCIATED WITH REAL WORLD PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH BRAF V600 MUTATION-POSITIVE ADVANCED MELANOMA TREATED WITH COBIMETINIB COMBINED WITH VEMUIRAFENIB, USING SURVIVAL DECISION TREE TECHNIQUE

被引：0

作者：

Meyer, N. ^{[1
]}

Perol, D. ^{[2
]}

Duval-Modeste, A. B. ^{[3
]}

El Adaoui, L. ^{[4
]}

Lelarge, Y. ^{[4
]}

Niarra, R. ^{[5
]}

Pau, D. ^{[4
]}

Vauleon, T. ^{[6
]}

Gilberg, M. ^{[4
]}

Mateus, C. ^{[7
]}

机构：

[1] IUCT Oncopole, Toulouse, France

[2] Ctr Leon Berard, Lyon, France

[3] Charles Nicolle Univ Hosp, Rouen, France

[4] Roche, Boulogne, France

[5] Keyrus Biopharma, Levallois Perret, France

[6] Lincoln Roche, Boulogne, France

[7] Gustave Roussy Inst, Villejuif, France

来源：

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PCN1

引用

页码：S435 / S435

页数：1